BioSpace News Archive

Kodiak Sciences Inc. announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3 clinical trials of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with diabetic macular edema.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022.

Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2022 revenues of $45.5 billion, an increase of 9% from the second quarter of last year.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 31 newly-hired employees stock options to purchase an aggregate of 213,500 shares, and restricted stock units covering an aggregate of 24,700 shares, of BioCryst common stock.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the appointment of three key team members to lead the company’s planned expansion into the U.S. market.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release fourth-quarter and full-year 2021 financial results before the market opens on Thursday, February 17, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.